Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.

8522Background: Early stage non-small-cell lung cancer (NSCLC) could benefit from anti-programmed cell death-1 (PD-1) monotherapy; however, the survival profiles remain to be disclosed. Here, we pr...